LIFE SCIENCE LIVE 2019
Artificial Intelligence & Health –
May 15–16, Turku Fair and Congress Center
Plenary. IBM: Andrew Fried, IBM Global Life Sciences Industry Leader
Ida Erling, Labrox Founder & CEO, Labrox Oy
Part One of Session One. Confirmed Speakers:
Professor Moncef Grabbouj, University of Tampere
Real-Time Patient-Specific ECG Classification by Convolutional Neural Networks
In this talk, we shall discuss how we approach AI from a signal processing, pattern recognition and machine learning point of view to solve pertinent problems in many areas, including biomedical signal processing. We present a hierarchical layered approach that exploits different types of sensor and non-sensor signals and design suitable representation, processing and analysis algorithms in order to apply machine learning, including deep and shallow learning. We shall then exploit the layered approach in a wide array of applications, with specific emphasis on ECG classification, where we shall present a fast and accurate patient-specific electrocardiogram (ECG) classification and monitoring system. The proposed system uses an adaptive implementation of 1D Convolutional Neural Networks (CNNs) which is used to fuse the two major blocks of the ECG classification into a single learning body: feature extraction and classification. For each patient, an individual and simple CNN will be trained using a relatively short segment of patient ECG training data. The proposed solution can be used for real-time ECG monitoring and early alert system on a light-weight wearable device. We will also show that the network can be used to classify possibly long ECG data accurately. The results over the MIT-BIH arrhythmia benchmark database demonstrate that the proposed solution achieves a superior classification compared to the state-of-the-art methods for the detection of ventricular ectopic beats (VEB) and supraventricular ectopic beats (SVEB).
Professor Martin Cowie, Imperial College London
Learning lessons the hard way in remote monitoring of complex cardiac disease
10.30 Opening words by the Chair of the day. Jari Forsström, Abomics Oy and Healthtech Finland, Genomic Industry SIG
10.45 Finnish biotech year 2018. Tero Piispanen, HealthTurku, Turku Science Park Oy
11.15 Are there any more traditional Venture Capitalists? Walter Stockinger, Hadean Ventures
Evidencing value based care through hospital EHRs and ICHOM standards: Thomas Allvin, EFPIA
The hospital perspective: Juuso Blomster, University of Turku
The pharma industry perspective: Bart Vannieuwenhuyse, Janssen
The patient perspective: Peter van Galen, Belgium, Patient representative
Sammeli Liikkanen, Chief digital officer, Orion Corporation, Orion PharmaOrion
Arho Virkki, Adjuct Professor of Medical Mathematics at University of Turku, Head of Auria Clinical Informatics
Peter Essen, Bayer
Kristoffer Miving, Digital lead, Nordics & Baltics, Janssen
Tommi Lehtonen, CEO, Blueprint Genetics Oy
Lee Tien, Technology & Innovation Manager, PerkinElmer Inc.
Ilkka Räsänen, Leading Expert, Sitra
Part Two of Session One. Confirmed Speakers:
Professor Ion Petre, University of Turku
Network Controllability: Algorithmics for precision cancer medicine:
Jason Swedlow,Centre for Gene Regulation & Expression, University of Dundee, UK, Glencoe Software Inc., Seattle, WA
OME’s Bio-Formats, OMERO, & IDR: Open Tools for Accessing, Integrating, Mining and Publishing Image Data @ Scale
Measuring and improving data quality in hospitals:
Professor Pascal Coorevits, i~HD and University of Gent
Frank Staelens, OLV Hospital Aalst, Belgium
Complying with the GDPR when reusing real world data for research:
Dr Nathan Lea, i~HD and University College London
Saara Malkamäki, SITRA
Dr Filip De Meyer, i~HD and University of Gent
15.15 The New Modalities Ecosystem project ; what is there for me? Antti Haapalinna, Orion Pharma Ltd
15.40 Creating Companies of Scale. Giles Dudley, Senior Business Developer, BioInnovation Institute (Novo Foundation)
16.05 How Business Finland can help drive innovation and international growth in Life Sciences. Helena Viita, PhD, Chief Advisor, SME & Midcap, Health & Wellbeing, Business Finland
16.20 Ending discussion. Jari Forsström, Business Finland
Dipak Kalra, President of the European Institute for Innovation through Health Data
Part One of Session Two
Professor Olli Raitakari, University of Turku
Epigenetic inheritance of disease risk – implications for public health
Dr. Laura Elo, University of Turku
Transforming data to knowledge for better healthcare: The rapid developments in modern biotechnology have enabled large-scale measurements of molecular events in health and disease. This has opened up new possibilities to improve clinical decision making and drug development. However, data alone are not enough but effective computational methods and models are needed. The focus of this talk is on computational approaches that enable robust and reproducible interpretation of the large-scale molecular as well as clinical data. The ultimate goal is to improve the diagnosis, prognosis and treatment of complex diseases, such as diabetes and cancer.
Opening remarks, Professor Dipak Kalra, President of i~HD
EHR2EDC, Nadir Ammour, Sanofi
EHDEN, Nigel Hughes, Janssen
Trillium II and the International Patient Summary, Catherine Chronaki, HL7 Europe
Digital Health Europe, Oliver Zobell, Scientific Officer eHealth, Jülich
Register for one-on-one partnering sessions
UK Department for International Trade (British Embassy Helsinki) and The Science & Innovation Network in collaboration with Scottish Development International and Turku University of Applied Sciences welcome you to discover how the UK triple helix of academia, industry and government utilises artificial intelligence as enabler in the health technology space.
The keynote speakers representing the following organisations to be announced and the final programme published closer to the date.
- The Alan Turing Institute – UK national institute for data science and AI
- UK Medicines Discovery Catapult
- iCAIRD (The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics)
Please join the discussion and come to network with like-minded professionals. Registration to the event closes on Monday 6 May. Please, register here
For any queries, please don’t hesitate to contact the organiser.
Dr. Leona Gilbert, Ph.D. / Te?ted Oy
Te?ted is revolutionizing the way tick-borne disease are diagnosed at a 90% cost reduction for the patient. 80 countries all over the globe are reporting people suffering from tick-borne diseases and WHO has indicated that this is only going to increase. Our team is committed to get the patient tested so they can be treated and recovery quicker.
Harri Sihto, PhD / Sartar Therapeutics
Sartar Therapeutics is a pre-clinical stage company that develops a personalized medicine treatment for gastrointestinal stromal tumor (GIST). The therapy innovation is based on discovery of novel therapy targets in GIST and repurposing and reformulation of an old drug, anagrelide.
BW Sergey Sadov / Health Samurai Finland Oy
The description of our company was added to the webpages of the Partnering Day event previously
Anni Mörö, PhD, MSc(Tech) / Eye group, Tampere University
Eye group from Tampere University combines stem cell based tools and functional biomaterials towards innovative therapies for the benefit of the patients. Our multidisciplinary team tackles blindness by developing novel stem cell based solutions for the corneal and retinal repair through cell transplantation. We have considerable experience in human pluripotent stem cells, ocular cells and biomaterials resulting in over 100 publications and 8 patent applications.
Tejesvi Mysore / Chain Antimicrobials Oy
Chain Antimicrobials is a Biotech company focusing on developing antimicrobial coated medical devices to prevent hospital-acquired infections. Our lead product, the peptide-coated urinary catheters (PAC) have generated positive results from the in-vitro studies and currently in the preclinical study phase. PAC will improve the quality of life of patients, reduces the severity of UTIs, the financial burden on patients/healthcare provider and no extra days in the hospitals.
Preethy Paul / Team Name: Anison, Abo Akademi University
Anison has developed an herbal ointment to remove warts, caused by Human papilloma virus (HPV). Currently available wart treatments are not totally effective and do not treat the HPV infection. The project is in the development phase and a start-up is planned to be established in the near future.
Sakari Lätti, Head of Software Development / Aurlide ltd
Aurlide ltd is specialised in computer-dependent drug discovery, with special interest in identification of protein-protein interaction (PPI) modulators and their hit-to-lead optimisation. Our technology is unique and enables conversion of undruggable PPIs to druggable – technique that is only available via us.
Wlodek Laskowski, Board Member, CFO / Cardiolyse Oy
Cardiolyse is an algorithm-powered cloud platform that collects and analyses any EСG device and leads-number data to provide personal EСG baseline heart health reports and deliver up to 2 months data-based predictions on dangerous heart events to timely prevent them.
The clear analytic summary of remote heart health monitoring indicates the autonomous nervous system status and accounts user’s HRV, temperature and lifestyle factors to help the high risk groups, like diabetes or elderly people, to forecast the rising dangerous heart events and make them preventable.
Part Two of Session Two
Dr. Antti Karlsson, Auria Biobank
Huge amounts of tissue samples and related patient information are gathered in biobanks. This combined with modern research tools and computing power creates vast amounts of possibilities. Using clear examples, I will shortly introduce different research projects we have done ranging from ordinary retrospective register studies all the way to using artificial intelligence in the analysis of patient dictations and histopathological images
Antti Kangas, CTO & Co-Founder, Nightingale Health Ltd
Chair: Dipak Kalra
Petri Virolainen,Hospital Director of Turku University Hospital. Chief Medical Officer
Use of pharmacogenetic data in connection with personalized pharmaceutical treatment: Jari Forström, Turku University Hospital and Abomics Ltd
Register for one-on-one partnering sessions
Sampo Sammalisto, Ph.D. Program manager, Personalised Health, Health & Wellbeing, Business Finland
Haastateltavana opiskelija Mona Halme.
Haastateltavana apulaisprofessori Mari Sandell Turun yliopiston funktionaalisten elintarvikkeiden kehittämiskeskuksesta
Haastateltavana bakteeriopin apulaisprofessori Jukka Hytönen Turun yliopistosta
Haastateltavana Auria Biopankin kehityspäällikkö Antti Karlsson